MISX
LIFE
Market cap4mUSD
Jul 15, Last price
1.28RUB
1D
-1.92%
1Q
-57.21%
Jan 2017
-92.27%
IPO
-94.72%
Name
Farmsintez PAO
Chart & performance
P/E
—
P/S
2.46
EPS
—
Vol. 1Y
—
Shs. 5Y
7.91%
Rev. 5Y
-11.74%
Div Yld LY
—
Div Yld TTM
—
Revenues
156m
-36.96%
Net income
-254m
L
CFO
0
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PJSC Pharmsynthez, a pharmaceutical enterprise, focuses on the investigation, production, and supply of both proprietary (officinal) and generic active pharmaceutical ingredients across Russia and the Commonwealth of Independent States (CIS). Its portfolio of branded medicines includes Neovir, Segidrin, Fenasid, and Penkrofton, which are employed in critical therapeutic areas such as oncology, gynecology, the management of immune deficiencies, and tuberculosis. Public Joint-Stock Company Pharmsynthez has also established a collaboration with HiFiBiO Therapeutics Inks for the clinical advancement and market introduction of their SARS-CoV-2 neutralizing antibody within Russia. The company, which began operations in 1996, is headquartered in St. Petersburg, Russia.
Key people
Kirill Mayorov
General Director (CEO) · since 2019
Sergey Bezhanov
Director · since 2017
Chairman of the Board
Steven Gorelik
Director · since 2007
Director
Roman Knyazev
Director · since 2013
Dmitry Kolosov
Director · since 2013
Petr Kruglyakov
Director · since 2019
Olga Shpichko
Director · since 2013
Valuation
Title RUB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||